Invention Application
- Patent Title: ESTABLISHMENT OF THERAPY AND DIAGNOSIS FOR ALLERGIC DISEASES THROUGH CONTROL OF IMMUNOGLOBULIN-BINDING PROTEIN
-
Application No.: US18714854Application Date: 2022-12-01
-
Publication No.: US20250025545A1Publication Date: 2025-01-23
- Inventor: Shinji Fukuda , Gaku Nakato , Nozomu Obana , Risako Furukawa
- Applicant: Kanagawa Institute of Industrial Science and Technology , University of Tsukuba , Metagen, Inc.
- Applicant Address: JP Ebina-shi; JP Tsukuba-shi; JP Tsuruoka-shi
- Assignee: Kanagawa Institute of Industrial Science and Technology,University of Tsukuba,Metagen, Inc.
- Current Assignee: Kanagawa Institute of Industrial Science and Technology,University of Tsukuba,Metagen, Inc.
- Current Assignee Address: JP Ebina-shi; JP Tsukuba-shi; JP Tsuruoka-shi
- Priority: JP2021-195941 20211202
- International Application: PCT/JP2022/044364 WO 20221201
- Main IPC: A61K39/02
- IPC: A61K39/02 ; C07K14/195
Abstract:
Determination of the mechanism of allergy development in which a bacterium of the family Lachnospiraceae, which is an enteric bacterium, including Ruminococcus gnavus is involved and developing a method for preventing or treating allergies by intervening in the mechanism. Since the Ibp protein from a bacterium of the family Lachnospiraceae is involved in development of allergies, allergic reactions occurring in vivo can be prevented by administration or induction of in vivo production of a substance that binds to the Ibp protein.
Information query
